Skip to main content

Uptravi Side Effects

Generic name: selexipag

Medically reviewed by Last updated on Feb 24, 2023.

Note: This document contains side effect information about selexipag. Some dosage forms listed on this page may not apply to the brand name Uptravi.


Common side effects of Uptravi include: diarrhea, headache, jaw pain, limb pain, myalgia, nausea, vomiting, and flushing. Other side effects include: anemia, and decreased appetite. Continue reading for a comprehensive list of adverse effects.

Applies to selexipag: intravenous powder for solution.

Serious side effects of Uptravi

Along with its needed effects, selexipag (the active ingredient contained in Uptravi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking selexipag:

Incidence not known

  • Blue lips and fingernails
  • blurred vision
  • chest pain
  • confusion
  • coughing that sometimes produces a pink frothy sputum
  • difficult, fast, noisy breathing
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • increased sweating
  • pale skin
  • swelling in the legs and ankles
  • unusual tiredness or weakness

Other side effects of Uptravi

Some side effects of selexipag may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

  • Dry, red, hot, or irritated skin
  • pain, redness, or swelling at the injection site

For Healthcare Professionals

Applies to selexipag: intravenous injection, oral tablet.


Very common (10% or more): Flushing (up to 12%), sinus tachycardia (up to 11.3%)

Common (1% to 10%): Hypotension

Frequency not reported: Hot flush

Postmarketing reports: Symptomatic hypotension[Ref]


Very common (10% or more): Diarrhea (up to 42%), nausea (up to 34%), vomiting (up to 18%)

Common (1% to 10%): Abdominal pain, dyspepsia, abdominal discomfort

Frequency not reported: Ascites[Ref]


The most frequently reported side effects included headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing.[Ref]


Very common (10% or more): Rash (11%)

Common (1% to 10%): Urticaria, erythema[Ref]


Common (1% to 10%): Hyperthyroidism, thyroid stimulating hormone decreased[Ref]


Common (1% to 10%): Anemia, hemoglobin decreased[Ref]


Frequency not reported (injection): Infusion-site reactions (erythema, redness, pain, swelling)


Common (1% to 10%): Appetite decreased[Ref]


Very common (10% or more): Jaw pain (26%), pain in extremity (up to 17%), myalgia (up to 16%), arthralgia (up to 11%)

Common (1% to 10%): Musculoskeletal pain, neck pain

Frequency not reported: Bone pain[Ref]

Nervous system

Very common (10% or more): Headache (up to 65%)

Frequency not reported: Burning sensation[Ref]


Common (1% to 10%): Eye pain, retinal disorder[Ref]


Common (1% to 10%): Malignancy[Ref]


Common (1% to 10%): Asthenia, pyrexia, pain, influenza, weight decreased[Ref]


Frequency not reported: Acute renal failure


Very common (10% or more): Nasopharyngitis (13%)

Common (1% to 10%): Nasal congestion

Frequency not reported: Pulmonary veno-occlusive disease[Ref]

Frequently asked questions


1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc (2016):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.